CTLA4 and cancer: Appropriate levels of SCFAs can reduce intestinal inflammatory responses and provide energy for intestinal epithelial cells [24], yet aberrant expression levels of SCFAs may affect the therapeutic efficacy of CTLA‐4 antibodies in cancer patients [25].